CN120187720A - 4-[4-[3-氯-4-[1-(2-吡啶基)-2-羟基-乙氧基]吡唑并[1,5-a]吡啶-6-基]-5-甲基-三唑-1-基]哌啶-1-甲腈衍生物与没食子酸及烟酰胺的共晶形式 - Google Patents

4-[4-[3-氯-4-[1-(2-吡啶基)-2-羟基-乙氧基]吡唑并[1,5-a]吡啶-6-基]-5-甲基-三唑-1-基]哌啶-1-甲腈衍生物与没食子酸及烟酰胺的共晶形式 Download PDF

Info

Publication number
CN120187720A
CN120187720A CN202380077374.0A CN202380077374A CN120187720A CN 120187720 A CN120187720 A CN 120187720A CN 202380077374 A CN202380077374 A CN 202380077374A CN 120187720 A CN120187720 A CN 120187720A
Authority
CN
China
Prior art keywords
cancer
crystal form
bladder cancer
fgfr3
urothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380077374.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·科茨
L·R·希尔登
G·库米内克
J·A·彼得森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN120187720A publication Critical patent/CN120187720A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380077374.0A 2022-09-07 2023-09-06 4-[4-[3-氯-4-[1-(2-吡啶基)-2-羟基-乙氧基]吡唑并[1,5-a]吡啶-6-基]-5-甲基-三唑-1-基]哌啶-1-甲腈衍生物与没食子酸及烟酰胺的共晶形式 Pending CN120187720A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
US63/404,232 2022-09-07
PCT/US2023/073508 WO2024054814A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Publications (1)

Publication Number Publication Date
CN120187720A true CN120187720A (zh) 2025-06-20

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380077374.0A Pending CN120187720A (zh) 2022-09-07 2023-09-06 4-[4-[3-氯-4-[1-(2-吡啶基)-2-羟基-乙氧基]吡唑并[1,5-a]吡啶-6-基]-5-甲基-三唑-1-基]哌啶-1-甲腈衍生物与没食子酸及烟酰胺的共晶形式

Country Status (18)

Country Link
US (1) US20240116932A1 (https=)
EP (1) EP4584270A1 (https=)
JP (2) JP7541606B2 (https=)
KR (1) KR20250057022A (https=)
CN (1) CN120187720A (https=)
AR (1) AR130417A1 (https=)
AU (1) AU2023338199A1 (https=)
CA (1) CA3266872A1 (https=)
CL (1) CL2025000596A1 (https=)
CO (1) CO2025002467A2 (https=)
CR (1) CR20250077A (https=)
DO (1) DOP2025000054A (https=)
IL (1) IL319342A (https=)
JO (1) JOP20250053A1 (https=)
MX (1) MX2025002687A (https=)
PE (1) PE20251400A1 (https=)
TW (1) TWI862146B (https=)
WO (1) WO2024054814A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1962600B1 (en) * 2005-12-08 2013-05-01 New Form Pharmaceuticals Inc. Metronidazole cocrystals
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP3752159A4 (en) * 2018-02-13 2021-11-24 Transgenex Nanobiotech, Inc. NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Also Published As

Publication number Publication date
WO2024054814A1 (en) 2024-03-14
JP2024037713A (ja) 2024-03-19
CO2025002467A2 (es) 2025-03-17
CR20250077A (es) 2025-04-02
CA3266872A1 (en) 2024-03-14
JOP20250053A1 (ar) 2025-03-06
EP4584270A1 (en) 2025-07-16
JP7541606B2 (ja) 2024-08-28
US20240116932A1 (en) 2024-04-11
AU2023338199A1 (en) 2025-03-20
DOP2025000054A (es) 2025-03-31
CL2025000596A1 (es) 2025-04-25
PE20251400A1 (es) 2025-05-22
JP2024153948A (ja) 2024-10-29
KR20250057022A (ko) 2025-04-28
IL319342A (en) 2025-05-01
AR130417A1 (es) 2024-12-04
TWI862146B (zh) 2024-11-11
MX2025002687A (es) 2025-04-02
TW202428260A (zh) 2024-07-16

Similar Documents

Publication Publication Date Title
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
JP7118349B2 (ja) ｃ－ＭＥＴ阻害剤の結晶形、及びその塩形、並びに調製方法
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
CN120187720A (zh) 4-[4-[3-氯-4-[1-(2-吡啶基)-2-羟基-乙氧基]吡唑并[1,5-a]吡啶-6-基]-5-甲基-三唑-1-基]哌啶-1-甲腈衍生物与没食子酸及烟酰胺的共晶形式
CN108699081A (zh) 一种大环化合物及包含该化合物的组合物
WO2022078403A1 (zh) 取代的吡啶酮化合物及应用
WO2024109871A1 (zh) 一种含氮杂环类化合物的可药用盐、晶型及制备方法
CN112020357B (zh) 含吲唑基的三并环类衍生物的盐及其晶型
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
CN111471048B (zh) 一种具有含氮桥环、螺环或并环结构的化合物及其用途
CN114478547B (zh) 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途
AU2020242723A1 (en) BTK inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
CN117800953A (zh) 一种2-芳香胺基嘧啶类化合物及其制备方法与应用
JP2023543080A (ja) ピロロ複素環系誘導体の結晶及びその製造方法
CN115397827B (zh) Fgfr4抑制剂的盐型、晶型及其用途
WO2023011428A1 (zh) Ripk1抑制剂的晶型及其酸式盐和其酸式盐的晶型
WO2022171117A1 (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
CN112174958A (zh) 一种吡啶并[2,3-d]嘧啶类化合物及其制备方法和用途
CN104447733B (zh) 1-苄基-2-吡咯啉酮-4-酰胺类化合物及其制备方法与应用
RS61833B1 (sr) Derivati piridohinazolina korisni kao inhibitori proteinske kinaze
JP2025536818A (ja) 縮合環式化合物の固体形態、及びその製造方法並びに使用
JP2025526715A (ja) ピリジノピリミジノン化合物の結晶、その酸塩、その酸塩の結晶及び使用
WO2025223477A1 (zh) 并环含氮化合物、其晶型及其制备方法和用途
KR20240045269A (ko) Fgfr4 억제제 산성염 및 이의 제조 방법과 응용
CN114907342A (zh) 含氮稠杂环化合物游离碱的多晶型及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination